Xellia

Xellia Pharmaceuticals ApS is a Danish pharmaceutical company specialising in the development and manufacture of active pharmaceutical ingredients (APIs) for anti-infective therapies. With over 120 years of experience, the company's fermentation-based production process is considered technically complex, requiring extensive process expertise developed over decades. Xellia supplies more than 500 pharmaceutical companies across over 80 countries and is a subsidiary of Novo Holdings.

The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.

Active drug substances manufactured are:^[2]

Previously the company also produced:

In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market.^{[13][14][15][16][17]}

Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war.^[18]

• List of Danish companies
• List of pharmaceutical companies